Table 1.

Vectibix meets Erbitux^a

Parameter	Erbitux	Vectibix
Components	Chimeric human and mouse	Human only
FDA-approved indication	EGFR-expressing metastatic colorectal cancer	EGFR-expressing metastatic colorectal cancer
Patient profile	Patients intolerant to Camptosar (irinotecan) (chemotherapy)	Patients with disease progression or after chemotherapy
Administration	Loading dose (400 mg/m2 i.v.) Weekly (250 mg/m2 i.v.)	6 mg/kg every 14 days
Common toxicities
Dermatologic	8% (grade 3)	14% (grade 3–4)
Infusion reaction	2% (grade 3–4)	1% (grade 3–4)
Diarrhea	2% (grade 3–4)	2% (grade 3–4)
Pulmonary	interstitial lung disease <0.5%	pulmonary fibrosis < 1%
Clinical effects	10% response; 32% stable disease	10% response; 28% stable disease
Immunoglobulin subtype	IgG1	IgG2
Cost/monthb	$12,000c	$9,599.94d

^aData taken from ref 8 and 9 and literature search.

^bBased on average wholesale price for maintenance therapy only.

^cBased on body surface of 1.7.m² rounded up to the nearest vial size of 100 mg.

^dBased on 70-kg patient rounded up to the nearest vial size of 100 mg.